Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 17/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.47 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538211 | 1.00 | IDO1 (0.51) | IDO1DGAT1SOAT1SOAT2ALDH1A1 | |
| SCHEMBL13008026 | 0.86 | KDM4E (0.46) | IDO1DGAT1SOAT1ALDH1A1GAA | |
| SCHEMBL14199019 | 0.86 | KDM4E (0.46) | IDO1DGAT1SOAT1ALDH1A1GAA | |
| SCHEMBL3546428 | 0.84 | KDM4E (0.47) | IDO1DGAT1SOAT1ALDH1A1GAA | |
| SCHEMBL3546424 | 0.84 | KDM4E (0.47) | IDO1DGAT1SOAT1ALDH1A1GAA | |
| SCHEMBL3541478 | 0.82 | NPC1 (0.53) | IDO1DGAT1SOAT1ALDH1A1GAA | |
| SCHEMBL3541484 | 0.82 | NPC1 (0.53) | IDO1DGAT1SOAT1ALDH1A1GAA | |
| SCHEMBL3540578 | 0.81 | DGAT1 (0.44) | IDO1DGAT1SOAT1ALDH1A1GAA | |
| SCHEMBL3540582 | 0.81 | DGAT1 (0.44) | IDO1DGAT1SOAT1ALDH1A1GAA | |
| SCHEMBL3297351 | 0.81 | IDO1 (0.60) | IDO1DGAT1SOAT1SOAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | IDO1 2690/4885DGAT1 1/4885SOAT1 7/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | IDO1 2567/4885DGAT1 1/4885SOAT1 7/4885 |
| US-20090215779-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT2, GPR119, DGAT1 | IDO1 2912/4885DGAT1 3/4885SOAT1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.